Abstract
Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinician. Despite the prevalence and interest in A. baumannii infections, there is relatively limited well-controlled scientific data to help the clinician select optimal empirical and subsequent targeted therapy for a variety of infections. We will review the currently available antimicrobial agents and discuss the clinical data supporting the use of the various agents.
| Original language | English |
|---|---|
| Pages (from-to) | 79 - 84 |
| Number of pages | 6 |
| Journal | Clinical Infectious Diseases |
| Volume | 51 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2010 |